CD274 and cancer: The breakthrough in understanding immune checkpoints and the subsequent advancement of drugs, particularly monoclonal antibodies targeting programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1), represents a pivotal moment in the landscape of cancer immunotherapy [384].